Michael J Hageman
Overview
Explore the profile of Michael J Hageman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jafari N, Addison C, Lou H, Hageman M
J Pharm Sci
. 2024 Nov;
114(2):1068-1076.
PMID: 39615879
Most of the peptide drugs are often delivered subcutaneously. The significant barrier in this type of peptide administration is the high concentration of formulation, which can lead to self-assembly and...
2.
Pfannenstiel J, Duong M, Cluff D, Sherrill L, Colquhoun I, Cadoux G, et al.
bioRxiv
. 2024 Nov;
PMID: 39554145
Coronaviruses (CoVs) can emerge from zoonotic sources and cause severe diseases in humans and animals. All CoVs encode for a macrodomain (Mac1) that binds to and removes ADP-ribose from target...
3.
Jafari N, Douglas J, Neuenswander S, Kelich P, Hageman M
J Pharm Sci
. 2024 Nov;
114(2):878-886.
PMID: 39491674
Cyclodextrin complexation has a potential to modulate the physicochemical properties of peptide drugs. The ability of peptides to form an inclusion complex can be influenced by factors such as size,...
4.
Dening T, Napolitano J, Ochoa J, Douglas J, Hageman M
J Pharm Sci
. 2024 Oct;
114(1):434-448.
PMID: 39454943
There is growing interest in the oral delivery of poorly permeable peptide drugs; however, the effect of biorelevant colloids found in the aqueous gastrointestinal environment on peptide drug solution behavior...
5.
Lou H, Hu G, Luan X, Steinbach-Rankins J, Hageman M
J Pharm Sci
. 2024 Sep;
114(1):256-264.
PMID: 39278591
To date, the commonly used methods for diffusion coefficient measurements have some hurdles that prevent them from being widely applied in pharmaceutical laboratories. This study aimed to modify a method...
6.
Smith-Craven M, Dening T, Basra A, Hageman M
J Pharm Sci
. 2024 May;
113(8):2454-2463.
PMID: 38701896
Amphotericin B (AmB) is the gold standard for antifungal therapy; however, its poor solubility limits its administration via intravenous infusion. A promising formulation strategy to achieve an oral formulation is...
7.
Lou H, Luan X, Hu G, Hageman M
Int J Pharm
. 2024 Feb;
654:123940.
PMID: 38408551
This study aims to develop a new method to dry proteins based on protein-hyaluronic acid (HA) precipitation and apply the precipitation-redissolution technique to develop highly concentrated protein formulations. Lysozyme was...
8.
Lou H, Zhang Y, Kuczera K, Hageman M, Schoneich C
Mol Pharm
. 2023 Dec;
21(2):501-512.
PMID: 38128475
Molecular dynamics simulations were employed to investigate the interaction between Fe(III) and an iron-binding site composed of THR259, ASP252, and GLU261 on the Fc domain of an IgG1. The goal...
9.
Maji A, Soutar C, Zhang J, Lewandowska A, Uno B, Yan S, et al.
Nature
. 2023 Nov;
623(7989):1079-1085.
PMID: 37938782
Decades of previous efforts to develop renal-sparing polyene antifungals were misguided by the classic membrane permeabilization model. Recently, the clinically vital but also highly renal-toxic small-molecule natural product amphotericin B...
10.
Lou H, Hageman M
AAPS J
. 2023 Mar;
25(3):29.
PMID: 36949301
We recently developed an in vitro testing system, namely, ESCAR (Emulator of SubCutaneous Absorption and Release). The objective of this work was to investigate drug release behaviors of unmilled and...